Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections.
Frippiat
Frédéric
F
Meunier
Françoise
F
Derue
Geneviève
G
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001372:Aza Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D001850:Bone Diseases, Infectious / Q000188:drug therapy / Q000382:microbiology; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D006095:Gram-Positive Cocci / Q000187:drug effects*; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use*; D012293:Rifampin / Q000494:pharmacology / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin; D012293:Rifampin